American Century Companies
BCRX icon

American Century Companies’s BioCryst Pharmaceuticals BCRX Stock Holding History

American Century Companies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,385
Closed -$822K – 2840
2025
Q4 		$822K Sell
105,385
-10,905
-9% -$78.8K ﹤0.01% 2380
2025
Q3 		$883K Buy
116,290
+99,959
+612% +$832K ﹤0.01% 2340
2025
Q2 		$146K Sell
16,331
-121,382
-88% -$1.13M ﹤0.01% 2773
2025
Q1 		$1.03M Sell
137,713
-17,332
-11% -$140K ﹤0.01% 2242
2024
Q4 		$1.17M Sell
155,045
-330
-0.2% -$2.5K ﹤0.01% 2210
2024
Q3 		$1.18M Buy
155,375
+6,885
+5% +$52.3K ﹤0.01% 2178
2024
Q2 		$918K Buy
148,490
+133,591
+897% +$737K ﹤0.01% 2198
2024
Q1 		$75.7K Hold
14,899
– – ﹤0.01% 2880
2023
Q4 		$89.2K Hold
14,899
– – ﹤0.01% 2821
2023
Q3 		$105K Hold
14,899
– – ﹤0.01% 2717
2023
Q2 		$105K Sell
14,899
-51
-0.3% -$409 ﹤0.01% 2671
2023
Q1 		$125K Sell
14,950
-192
-1% -$1.85K ﹤0.01% 2512
2022
Q4 		$174K Buy
+15,142
New +$189K ﹤0.01% 2361
2022
Q2 		– Sell
-59,450
Closed -$967K – 2313
2022
Q1 		$967K Buy
59,450
+19,419
+49% +$311K ﹤0.01% 1690
2021
Q4 		$554K Buy
+40,031
New +$530K ﹤0.01% 1881

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

American Century Companies's BCRX Position: Q1 2026 in Review

American Century Companies sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 105,385 shares — an estimated $822K sold.

American Century Companies first reported a position in BCRX in Q4 2021 and held it in 15 quarters. The position peaked at $1.18M in Q3 2024. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • American Century Companies reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • American Century Companies sold 105,385 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $822K.
  • American Century Companies first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • American Century Companies's BioCryst Pharmaceuticals position peaked at $1.18M in Q3 2024.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.